Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

Completed · Phase 3

Conditions studied: Attention-Deficit/Hyperactivity Disorder

In brief

Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients

Key facts

Study ID
NCT04143217
Run by
Supernus Pharmaceuticals, Inc.
People needed
159
Starts
2020-01-23
Expected to finish
2022-12-14
Last updated by the study team
2024-02-13

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.